Matt Hewitt
Stock Analyst at Craig-Hallum
(2.68)
# 2,199
Out of 5,090 analysts
40
Total ratings
54.05%
Success rate
3.32%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $19.64 | +83.30% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.04 | +98.68% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.58 | +132.56% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.46 | +25.69% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $40.50 | +58.04% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.81 | +1,138.08% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $17.64 | +70.07% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.47 | +376.19% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $164.98 | +21.23% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.95 | +412.82% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.59 | +295.26% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.48 | +82,672.89% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $19.64
Upside: +83.30%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.04
Upside: +98.68%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.58
Upside: +132.56%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.46
Upside: +25.69%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $40.50
Upside: +58.04%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.81
Upside: +1,138.08%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $17.64
Upside: +70.07%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.47
Upside: +376.19%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $164.98
Upside: +21.23%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.95
Upside: +412.82%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.59
Upside: +295.26%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.48
Upside: +82,672.89%